CNS Pharmaceuticals, Inc. Net Income Loss

Quick Answer

CNS Pharmaceuticals, Inc. reported Net Income Loss of -$15.85 million for the year ending 2025.

  • CNS Pharmaceuticals, Inc. showed a decrease of -6.7% in Net Income Loss from 2024 to 2025.
  • This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), CNS Pharmaceuticals, Inc.'s Net Income Loss has declined by 114.4%.
  • Historical annual values: Fiscal year 2025: -$15.85 million | Fiscal year 2024: -$14.86 million | Fiscal year 2023: -$18.85 million | Fiscal year 2022: -$15.27 million | Fiscal year 2021: -$14.50 million | Fiscal year 2020: -$9.46 million | Fiscal year 2019: -$3.88 million | Fiscal year 2018: -$7.39 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: